Skip to content
AnimalTargeted fat-depot destruction via vascular apoptosis

Adipotide (FTTP)

Also indexed as FTTP, Pro-Gly-Trp-Leu-Ala-Glu-Gly-Trp-Gly-Gly-Cys-NH2 (D[KLAKLAK]2), Prohibitin-targeting peptide

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

Overview

Following subcutaneous administration, Adipotide distributes systemically. PHB1 surface expression on adipose vasculature provides the selectivity filter. Internalization triggers mitochondrial outer membrane permeabilization (MOMP), Bax/Bak-independent, leading to apoptosis. Renal clearance of the peptide and its fragments is the primary elimination pathway, explaining the observed nephrotoxicity — likely due to non-specific uptake or renal tubular accumulation of the lytic domain.

Proposed mechanism

Adipotide is a chimeric peptide containing two functional domains: a targeting sequence (CKGGRAKDC) that homes to prohibitin expressed on the luminal surface of blood vessels feeding white adipose tissue, and a pro-apoptotic domain (D[KLAKLAK]2) that disrupts mitochondrial membranes upon internalization. This dual action induces apoptosis specifically in adipose vasculature endothelial cells, cutting off blood and nutrient supply to fat depots and triggering adipocyte death via ischemia, ultimately leading to reduction in fat mass.

What the evidence supports

Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Graded Animal

Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Reversal of obesity by targeted ablation of adipose tissue

    · Nature Medicine, Kolonin MG et al. doi:10.1038/nm1048 · 2004

  2. [2]

    Targeting the tumor microenvironment and obesity in cancer treatment: A phase I clinical trial

    · Science Translational Medicine, Barnhart KF et al. doi:10.1126/scitranslmed.3002621 · 2011

  3. [3]

    Prohibitin as a surface receptor in adipose tissue vasculature

    · Proceedings of the National Academy of Sciences, Kolonin MG et al. · 2006

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.